Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

Pharmaceutical Applications of Cellulose Ethers and Cellulose Ether Esters.

Arca HC, Mosquera-Giraldo LI, Bi V, Xu D, Taylor LS, Edgar KJ.

Biomacromolecules. 2018 Jul 9;19(7):2351-2376. doi: 10.1021/acs.biomac.8b00517. Epub 2018 Jun 22. Review.

PMID:
29869877
2.

Influence of pressurized carbon dioxide on ketoprofen-incorporated hot-melt extruded low molecular weight hydroxypropylcellulose.

A Ashour E, Kulkarni V, Almutairy B, Park JB, Shah SP, Majumdar S, Lian Z, Pinto E, Bi V, Durig T, Martin ST, Repka MA.

Drug Dev Ind Pharm. 2016 Jan;42(1):123-130. Epub 2015 May 22.

3.

Development of taste masked caffeine citrate formulations utilizing hot melt extrusion technology and in vitro-in vivo evaluations.

Pimparade MB, Morott JT, Park JB, Kulkarni VI, Majumdar S, Murthy SN, Lian Z, Pinto E, Bi V, Durig T, Murthy R, Shivakumar HN, Vanaja K, Kumar PC, Repka MA.

Int J Pharm. 2015 Jun 20;487(1-2):167-76. doi: 10.1016/j.ijpharm.2015.04.030. Epub 2015 Apr 15.

4.

Expression of ORAII, a plasma membrane resident subunit of the CRAC channel, in rodent and non-rodent species.

Guzman R, Valente EG, Pretorius J, Pacheco E, Qi M, Bennett BD, Fong DH, Lin FF, Bi V, McBride HJ.

J Histochem Cytochem. 2014 Dec;62(12):864-78. doi: 10.1369/0022155414554926. Epub 2014 Sep 23.

5.

Evaluation of the recrystallization kinetics of hot-melt extruded polymeric solid dispersions using an improved Avrami equation.

Feng X, Ye X, Park JB, Lu W, Morott J, Beissner B, Lian ZJ, Pinto E, Bi V, Porter S, Durig T, Majumdar S, Repka MA.

Drug Dev Ind Pharm. 2015;41(9):1479-87. doi: 10.3109/03639045.2014.958755. Epub 2015 Jul 21.

6.

Mouse monoclonal antibodies to transient receptor potential ankyrin 1 act as antagonists of multiple modes of channel activation.

Lee KJ, Wang W, Padaki R, Bi V, Plewa CA, Gavva NR.

J Pharmacol Exp Ther. 2014 Aug;350(2):223-31. doi: 10.1124/jpet.114.215574. Epub 2014 Jun 3.

PMID:
24893987
7.

Development of a human antibody tolerant mouse model to assess the immunogenicity risk due to aggregated biotherapeutics.

Bi V, Jawa V, Joubert MK, Kaliyaperumal A, Eakin C, Richmond K, Pan O, Sun J, Hokom M, Goletz TJ, Wypych J, Zhou L, Kerwin BA, Narhi LO, Arora T.

J Pharm Sci. 2013 Oct;102(10):3545-55. doi: 10.1002/jps.23663. Epub 2013 Aug 7.

PMID:
23925953
8.

FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.

Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.

J Clin Invest. 2012 Jul;122(7):2543-53. doi: 10.1172/JCI61405. Epub 2012 Jun 25.

9.

Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible alpha-cell hyperplasia and hyperglucagonemia.

Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, Shen Y, Hu S, Boone T, Lindberg RA, VĂ©niant MM.

J Pharmacol Exp Ther. 2009 Dec;331(3):871-81. doi: 10.1124/jpet.109.157685. Epub 2009 Aug 31.

PMID:
19720878
10.

Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys.

Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ, Caughey D, Elliott GS, Lau YY, Wang J, Li YS, Boone T, Lindberg RA, Hu S, VĂ©niant MM.

J Pharmacol Exp Ther. 2009 Apr;329(1):102-11. doi: 10.1124/jpet.108.147009. Epub 2009 Jan 7.

PMID:
19129372

Supplemental Content

Support Center